MedTrace Logo

Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification

NCT02084576 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-03-12

No results posted yet for this study

Summary

To compare the anti-inflammatory efficacy of ketorolac of tromethamine 0.4% and nepafenac 0.1% eye drops for prophylaxis of cystoid macular edema (CME) after small-incision cataract extraction.

Conditions

  • Cystoid Macular Edema
  • Cataract

Interventions

DRUG

Nepafenac

One drop in the study eye 3 times daily for 30 days

DRUG

Ketorolac

One drop in the study eye 4 times daily for 30 days

Sponsors & Collaborators

  • Hospital Oftalmologico de Brasilia

    lead OTHER

Principal Investigators

  • Patrick F Tzelikis, MD, PhD · Hospital Oftalmologico de Brasilia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2013-08-31
Completion
2014-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084576 on ClinicalTrials.gov